FierceBiotech 17 abr 2026 A new benchmark for biotech IPOs? Kailera raises $625M to fund obesity pipeline
FierceBiotech 17 abr 2026 Small pools, big ideas: How the rare disease community is reimagining clinical trials
FierceBiotech 16 abr 2026 RyghtAI launches clinical site search engine to aid drug developers, CROs with trial design
FierceBiotech 16 abr 2026 Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal
FierceBiotech 16 abr 2026 Pfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial
FierceBiotech 16 abr 2026 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
FierceBiotech 16 abr 2026 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
FierceBiotech 16 abr 2026 FDA advisory committee set to weigh taking action on certain unapproved peptides
FierceBiotech 15 abr 2026 Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?
FierceBiotech 15 abr 2026 Spain sets up Boston-focused VC fund with goal of raising $200M for biotechs
FierceBiotech 15 abr 2026 Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
FierceBiotech 15 abr 2026 Bain-backed Beeline Medicines buzzes out of stealth with $300M and 5 programs from BMS